CU20170073A7 - Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos - Google Patents
Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismosInfo
- Publication number
- CU20170073A7 CU20170073A7 CUP2017000073A CU20170073A CU20170073A7 CU 20170073 A7 CU20170073 A7 CU 20170073A7 CU P2017000073 A CUP2017000073 A CU P2017000073A CU 20170073 A CU20170073 A CU 20170073A CU 20170073 A7 CU20170073 A7 CU 20170073A7
- Authority
- CU
- Cuba
- Prior art keywords
- substituted
- alkyl
- halogens
- compounds
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical group C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 150000002367 halogens Chemical class 0.000 abstract 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
<p>La presente invención se refiere a Compuestos de fórmula general (I)</p> <p>ESPACIO PARA FÓRMULA</p> <p>en donde:</p> <p>R1 representa alquilo C1-C6, en donde el radical alquilo C1-C6 puede estar sustituido con 1, 2, 3 halógenos, o uno o dos grupos hidroxi, un cicloalquilo C3-C6 que puede estar sustituido con 1,2,3 halogenos, un radical R6, R7SO2, R7SO o R8O</p> <p>o representa un grupo seleccionado de:</p> <p>ESPACIO PARA FÓRMULA</p> <p>en donde * representa un sitio de unión del grupo con el radical de la molécula;</p> <p>R2 y R3 siempre tienen el mismo significado y al mismo tiempo representan hidrogeno o alquilo C1-C6;</p> <p>R4 representa halógeno, ciano, alquilo C1-C6 que puede estar sustituido con 1, 2, 3 halógenos, un grupo hidroxi o cicloalquilo C3-C6 que puede estar sustituido por 1, 2, 3 halógenos, o un grupo hidroxi;</p> <p>R5 representa hidrógeno, halógeno o un alquilo C1-C6 que puede estar sustituido con 1, 2, 3 halógenos;</p> <p>R6 representa un heterociclo saturado monocíclico que puede estar mono o disustituido con metilo con 4 a 6 átomos del anillo, que contiene un heteroátomo o un heterogrupo de la serie O, S, SO y SO2;</p> <p>R7 representa alquilo C1-C6, en donde el radical alquilo C1-C6 puede estar sustituido con 1, 2 o 3 halógenos, hidroxi o cicloalquilo C3-C6; o R7 representa cicloalquilo C3-C6;</p> <p>R8 representa alquilo C1-C6, en donde el radical alquilo C1-C6 puede estar sustituido con 1,2 o 3 halógenos.</p> <p>También se revelan compuestos de la fórmula general (III),</p> <p>ESPACIO PARA FÓRMULA</p> <p>en donde R1, R4 y R5 son como se definen en las reivindicaciones. Dichos compuestos de fórmula (III) son útiles como intermediarios para la preparación de compuestos de fórmula (I).</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14195032 | 2014-11-26 | ||
| PCT/EP2015/077596 WO2016083433A1 (de) | 2014-11-26 | 2015-11-25 | Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten sowie deren verwendung zur herstellung von arzneimitteln |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20170073A7 true CU20170073A7 (es) | 2017-10-05 |
| CU24448B1 CU24448B1 (es) | 2019-10-04 |
Family
ID=51982455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2017000073A CU24448B1 (es) | 2014-11-26 | 2015-11-25 | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos |
Country Status (42)
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3092226B1 (en) | 2014-01-10 | 2019-03-13 | Aurigene Discovery Technologies Limited | Indazole compounds as irak4 inhibitors |
| LT3466955T (lt) | 2014-01-13 | 2021-02-25 | Aurigene Discovery Technologies Limited | Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas |
| JO3705B1 (ar) * | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| TW201701879A (zh) * | 2015-04-30 | 2017-01-16 | 拜耳製藥公司 | Ｉｒａｋ４抑制劑組合 |
| EP3195865A1 (de) * | 2016-01-25 | 2017-07-26 | Bayer Pharma Aktiengesellschaft | Kombinationen von irak4 inhibitoren und btk inhibitoren |
| JP6871919B2 (ja) | 2015-06-16 | 2021-05-19 | ナノファギックス エルエルシー | 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法 |
| WO2017148902A1 (de) | 2016-03-03 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| EP3219329A1 (en) * | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
| EP3448849B1 (en) * | 2016-04-29 | 2020-05-13 | Bayer Pharma Aktiengesellschaft | Synthesis of indazoles |
| EA035867B1 (ru) * | 2016-04-29 | 2020-08-24 | Байер Фарма Акциенгезельшафт | Синтез индазолов |
| WO2017186689A1 (en) * | 2016-04-29 | 2017-11-02 | Bayer Pharma Aktiengesellschaft | Synthesis of indazoles |
| SG10202011653WA (en) * | 2016-06-01 | 2020-12-30 | Bayer Pharma AG | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases |
| MX394560B (es) * | 2016-06-01 | 2025-03-24 | Bayer Pharma AG | Uso de indazoles sustituidos para el tratamiento y la prevencion de enfermedades en animales. |
| CN115819417A (zh) | 2016-09-09 | 2023-03-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途 |
| US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| WO2018060072A1 (de) | 2016-09-29 | 2018-04-05 | Bayer Pharma Aktiengesellschaft | Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| TW202340194A (zh) | 2017-02-16 | 2023-10-16 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| EP3600270B1 (en) | 2017-03-31 | 2023-06-14 | Aurigene Oncology Limited | Compounds and compositions for treating hematological disorders |
| US11957931B2 (en) | 2017-04-26 | 2024-04-16 | Yale University | Compositions and methods for treating vitiligo |
| US11427573B2 (en) | 2017-08-16 | 2022-08-30 | Vanderbilt University | Indazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| IL315310A (en) * | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| KR20200121800A (ko) | 2018-01-05 | 2020-10-26 | 싸이브렉사 1, 인크. | 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법 |
| EP3755703B1 (en) | 2018-02-20 | 2022-05-04 | Incyte Corporation | N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| CN112638430B (zh) | 2018-06-27 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 放射性标记的大麻素受体2配体 |
| JP7478672B2 (ja) | 2018-06-27 | 2024-05-07 | エフ． ホフマン－ラ ロシュ アーゲー | カンナビノイド受容体２の阻害剤としての新規なアゼチジン置換ピリジン及びピラジン化合物 |
| CA3096777A1 (en) | 2018-06-27 | 2020-02-02 | F. Hoffmann-La Roche Ag | Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
| TWI842978B (zh) | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| CN110835338A (zh) * | 2018-08-17 | 2020-02-25 | 浙江海正药业股份有限公司 | 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途 |
| WO2020035019A1 (zh) * | 2018-08-17 | 2020-02-20 | 浙江海正药业股份有限公司 | 吲唑胺类衍生物及其制备方法和其在医药上的用途 |
| WO2020068729A1 (en) | 2018-09-25 | 2020-04-02 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators |
| CN111362920B (zh) * | 2018-12-25 | 2024-06-07 | 上海美悦生物科技发展有限公司 | 一种作为irak抑制剂的化合物 |
| US20220204473A1 (en) * | 2018-12-25 | 2022-06-30 | Shanghai Meiyue Biotech Development Co., Ltd. | Compound as irak inhibitor |
| CN111499612B (zh) * | 2019-01-30 | 2022-12-30 | 上海美悦生物科技发展有限公司 | 一种作为irak抑制剂的化合物及其制备方法和用途 |
| CN111560012B (zh) * | 2019-02-14 | 2023-06-23 | 上海美悦生物科技发展有限公司 | 一种作为irak抑制剂的化合物 |
| CN111793064B (zh) * | 2019-04-02 | 2023-06-23 | 上海美悦生物科技发展有限公司 | 一种作为irak抑制剂的化合物及其制备方法和用途 |
| WO2020259626A1 (zh) * | 2019-06-26 | 2020-12-30 | 南京明德新药研发有限公司 | 作为irak4抑制剂的咪唑并吡啶类化合物 |
| US20230002361A1 (en) * | 2019-06-27 | 2023-01-05 | Biogen Ma Inc. | 2h-indazole derivatives and their use in the treatment of disease |
| US11555019B2 (en) | 2019-07-10 | 2023-01-17 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
| MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| AU2020311940A1 (en) | 2019-07-11 | 2022-02-03 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as LRRK2 inhibitors |
| BR112022002059A2 (pt) | 2019-08-06 | 2022-06-07 | Incyte Corp | Formas sólidas de um inibidor de hpk1 |
| AU2020352311B2 (en) * | 2019-09-24 | 2023-11-09 | Wuhan Createrna Science And Technology Co., Ltd. | IRAK inhibitor and preparation method therefor and use thereof |
| CN111072634B (zh) * | 2020-01-03 | 2022-07-22 | 中国医科大学 | 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用 |
| CN113521079A (zh) * | 2020-04-20 | 2021-10-22 | 上海领泰生物医药科技有限公司 | Irak4抑制剂在治疗ali/ards中的应用 |
| US11866405B2 (en) | 2020-12-10 | 2024-01-09 | Astrazeneca Ab | Substituted indazoles as IRAK4 inhibitors |
| EP4319750A4 (en) | 2021-04-08 | 2025-02-26 | Curis, Inc. | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
| CN113278017B (zh) * | 2021-05-27 | 2023-03-28 | 上海应用技术大学 | 取代吲唑类化合物、制备方法、应用和包含其的组合物 |
| CN113402499B (zh) | 2021-06-21 | 2022-05-13 | 上海勋和医药科技有限公司 | 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途 |
| US20250018046A1 (en) * | 2021-07-07 | 2025-01-16 | Biogen Ma Inc | Compounds for targeting degradation of irak4 proteins |
| WO2023098857A1 (zh) * | 2021-12-03 | 2023-06-08 | 武汉人福创新药物研发中心有限公司 | Irak4抑制剂及其用途 |
| AU2023371864A1 (en) | 2022-11-04 | 2025-04-17 | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Irak4 degradation agent and use thereof |
| WO2024108010A1 (en) * | 2022-11-17 | 2024-05-23 | Bayer Animal Health Gmbh | Methods and compositions for control of pain and inflammation |
| CN116120283B (zh) * | 2022-12-13 | 2025-01-28 | 药康众拓(北京)医药科技有限公司 | 一种氘代啶酰胺类irak-4抑制剂药物及用途 |
| CN121773108A (zh) * | 2023-06-29 | 2026-03-31 | 同和药品株式会社 | 新的羧酰胺衍生物化合物及包含该化合物的药物组合物 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2246606B1 (es) | 2002-07-23 | 2007-06-01 | Izar Construcciones Navales S.A. | Unidad semi-sumergible auto-propulsada para transporte y engorde de peces vivos. |
| WO2004013102A1 (de) * | 2002-07-31 | 2004-02-12 | Schering Aktiengesellschaft | Vegfr-2 und vegfr-3 inhibitorische anthranylamidpyrimidene |
| CN100393698C (zh) | 2003-06-25 | 2008-06-11 | 第一药品(株) | 三环衍生物或其药学上可接受的盐、其制备以及包含它们的药物组合物 |
| WO2005082866A2 (en) | 2004-02-20 | 2005-09-09 | Pfizer Limited | Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists |
| US20080161365A1 (en) | 2004-12-08 | 2008-07-03 | Pfizer Inc. | Methylene Derivatives |
| TWI370820B (en) | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
| GB0518671D0 (en) * | 2005-09-13 | 2005-10-19 | Novartis Ag | Organic compounds |
| GT200600411A (es) * | 2005-09-13 | 2007-05-21 | Novartis Ag | Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular |
| US7745477B2 (en) | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
| EP1986643A1 (en) | 2006-02-10 | 2008-11-05 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| TWI435863B (zh) | 2006-03-20 | 2014-05-01 | Nihon Nohyaku Co Ltd | Ｎ-２-（雜）芳基乙基甲醯胺衍生物及含該衍生物之蟲害防治劑 |
| JP5258563B2 (ja) | 2006-06-29 | 2013-08-07 | 日産化学工業株式会社 | αアミノ酸誘導体及びそれを有効成分として含む医薬 |
| EP2061786A2 (en) * | 2006-09-07 | 2009-05-27 | Biogen Idec MA Inc. | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase |
| FR2917735B1 (fr) | 2007-06-21 | 2009-09-04 | Sanofi Aventis Sa | Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique |
| WO2009011850A2 (en) * | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| WO2009117421A2 (en) | 2008-03-17 | 2009-09-24 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| US20100094000A1 (en) | 2008-09-03 | 2010-04-15 | Takeda Pharmaceutical Company Limited | Pyrazole compounds |
| WO2011067364A1 (en) * | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Novel compounds |
| WO2011153588A1 (en) | 2010-06-10 | 2011-12-15 | Biota Scientific Management Pty Ltd | Viral polymerase inhibitors |
| WO2012061926A1 (en) | 2010-11-08 | 2012-05-18 | Zalicus Pharmaceuticals Ltd. | Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers |
| BR112013015460B1 (pt) * | 2010-12-20 | 2022-01-25 | Merck Serono S.A. | Derivados de indazolil triazol, kit, e composição farmacêutica |
| WO2012107475A1 (en) | 2011-02-10 | 2012-08-16 | Syngenta Participations Ag | Microbiocidal pyrazole derivatives |
| EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
| MX2013009393A (es) | 2011-02-18 | 2013-08-29 | Vertex Pharma | Piperidinamidas cromano-espirociclicas como moduladores de canales de iones. |
| WO2013106254A1 (en) | 2012-01-11 | 2013-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
| HK1206723A1 (en) | 2012-05-21 | 2016-01-15 | Bayer Pharma Aktiengesellschaft | Thienopyrimidines |
| JP2015002717A (ja) | 2013-06-21 | 2015-01-08 | 住友ベークライト株式会社 | 蓋付き容器 |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| EP3092226B1 (en) | 2014-01-10 | 2019-03-13 | Aurigene Discovery Technologies Limited | Indazole compounds as irak4 inhibitors |
| AU2015275730A1 (en) | 2014-06-20 | 2016-12-15 | Aurigene Discovery Technologies Limited | Substituted indazole compounds as IRAK4 inhibitors |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| TW201701879A (zh) | 2015-04-30 | 2017-01-16 | 拜耳製藥公司 | Ｉｒａｋ４抑制劑組合 |
| JP2018524372A (ja) | 2015-07-15 | 2018-08-30 | アウリジーン ディスカバリー テクノロジーズ リミテッド | Ｉｒａｋ−４阻害剤としてのインダゾール及びアザインダゾール化合物 |
| WO2017148902A1 (de) | 2016-03-03 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| EP3219329A1 (en) | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
| EP3448849B1 (en) | 2016-04-29 | 2020-05-13 | Bayer Pharma Aktiengesellschaft | Synthesis of indazoles |
| WO2017186689A1 (en) | 2016-04-29 | 2017-11-02 | Bayer Pharma Aktiengesellschaft | Synthesis of indazoles |
| SG10202011653WA (en) | 2016-06-01 | 2020-12-30 | Bayer Pharma AG | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases |
| MX394560B (es) | 2016-06-01 | 2025-03-24 | Bayer Pharma AG | Uso de indazoles sustituidos para el tratamiento y la prevencion de enfermedades en animales. |
-
2015
- 2015-11-23 JO JOP/2015/0287A patent/JO3705B1/ar active
- 2015-11-25 ES ES19191936T patent/ES2976932T3/es active Active
- 2015-11-25 NZ NZ732126A patent/NZ732126A/en unknown
- 2015-11-25 AU AU2015352603A patent/AU2015352603B2/en active Active
- 2015-11-25 EP EP23189515.2A patent/EP4260909A3/de not_active Withdrawn
- 2015-11-25 KR KR1020177017079A patent/KR102083857B1/ko not_active Expired - Fee Related
- 2015-11-25 UA UAA201909772A patent/UA123813C2/uk unknown
- 2015-11-25 RS RS20240330A patent/RS65327B1/sr unknown
- 2015-11-25 ME MEP-2020-115A patent/ME03745B/me unknown
- 2015-11-25 SG SG11201704092YA patent/SG11201704092YA/en unknown
- 2015-11-25 SG SG10201903474PA patent/SG10201903474PA/en unknown
- 2015-11-25 BR BR112017011005-9A patent/BR112017011005B1/pt active IP Right Grant
- 2015-11-25 EP EP15800828.4A patent/EP3224254B1/de active Active
- 2015-11-25 EP EP19191936.4A patent/EP3674298B9/de active Active
- 2015-11-25 BR BR122021002613-0A patent/BR122021002613B1/pt active IP Right Grant
- 2015-11-25 SI SI201531182T patent/SI3224254T1/sl unknown
- 2015-11-25 CU CU2017000073A patent/CU24448B1/es unknown
- 2015-11-25 US US15/529,996 patent/US10308634B2/en active Active
- 2015-11-25 HR HRP20200974TT patent/HRP20200974T1/hr unknown
- 2015-11-25 JP JP2017528139A patent/JP6496823B2/ja active Active
- 2015-11-25 ES ES15800828T patent/ES2796285T3/es active Active
- 2015-11-25 DK DK15800828.4T patent/DK3224254T3/da active
- 2015-11-25 EA EA201791137A patent/EA032509B1/ru not_active IP Right Cessation
- 2015-11-25 PL PL19191936.4T patent/PL3674298T3/pl unknown
- 2015-11-25 SI SI201532005T patent/SI3674298T1/sl unknown
- 2015-11-25 PL PL15800828T patent/PL3224254T3/pl unknown
- 2015-11-25 MX MX2020010623A patent/MX390119B/es unknown
- 2015-11-25 HR HRP20240414TT patent/HRP20240414T1/hr unknown
- 2015-11-25 SG SG10201903475TA patent/SG10201903475TA/en unknown
- 2015-11-25 FI FIEP19191936.4T patent/FI3674298T3/fi active
- 2015-11-25 PT PT191919364T patent/PT3674298T/pt unknown
- 2015-11-25 LT LTEP19191936.4T patent/LT3674298T/lt unknown
- 2015-11-25 MX MX2017006910A patent/MX380150B/es unknown
- 2015-11-25 DK DK19191936.4T patent/DK3674298T3/da active
- 2015-11-25 TN TN2017000226A patent/TN2017000226A1/en unknown
- 2015-11-25 PT PT158008284T patent/PT3224254T/pt unknown
- 2015-11-25 PE PE2017000922A patent/PE20171376A1/es unknown
- 2015-11-25 UA UAA201706382A patent/UA120948C2/uk unknown
- 2015-11-25 HU HUE15800828A patent/HUE049341T2/hu unknown
- 2015-11-25 CN CN201580073989.1A patent/CN107406416B/zh active Active
- 2015-11-25 CA CA2968614A patent/CA2968614C/en active Active
- 2015-11-25 HU HUE19191936A patent/HUE065938T2/hu unknown
- 2015-11-25 LT LTEP15800828.4T patent/LT3224254T/lt unknown
- 2015-11-25 MA MA41011A patent/MA41011B1/fr unknown
- 2015-11-25 WO PCT/EP2015/077596 patent/WO2016083433A1/de not_active Ceased
- 2015-11-25 RS RS20200564A patent/RS60284B1/sr unknown
- 2015-11-25 CR CR20170220A patent/CR20170220A/es unknown
- 2015-11-25 CN CN201910670725.4A patent/CN110305109B/zh active Active
- 2015-11-26 UY UY0001036411A patent/UY36411A/es active IP Right Grant
- 2015-11-26 TW TW108137338A patent/TWI717061B/zh active
- 2015-11-26 AR ARP150103876A patent/AR102827A1/es active IP Right Grant
- 2015-11-26 TW TW104139563A patent/TWI689502B/zh not_active IP Right Cessation
-
2017
- 2017-05-09 IL IL25218517A patent/IL252185B/en active IP Right Grant
- 2017-05-25 EC ECIEPI201732530A patent/ECSP17032530A/es unknown
- 2017-05-25 PH PH12017500972A patent/PH12017500972A1/en unknown
- 2017-05-26 NI NI201700063A patent/NI201700063A/es unknown
- 2017-05-26 DO DO2017000127A patent/DOP2017000127A/es unknown
- 2017-05-26 CL CL2017001364A patent/CL2017001364A1/es unknown
- 2017-06-26 CO CONC2017/0005374A patent/CO2017005374A2/es unknown
-
2019
- 2019-04-05 US US16/377,025 patent/US10793545B2/en active Active
- 2019-06-20 IL IL267537A patent/IL267537B/en active IP Right Grant
- 2019-09-19 IL IL269444A patent/IL269444B/en active IP Right Grant
-
2020
- 2020-02-11 AU AU2020200979A patent/AU2020200979B2/en active Active
- 2020-06-05 CY CY20201100506T patent/CY1123815T1/el unknown
- 2020-09-01 US US17/009,553 patent/US20210053941A1/en not_active Abandoned
-
2022
- 2022-07-20 US US17/869,674 patent/US12006304B2/en active Active
- 2022-07-20 US US17/869,673 patent/US12006303B2/en active Active
-
2024
- 2024-04-30 US US18/651,572 patent/US12559473B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20170073A7 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| PY1909256A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
| DOP2018000268A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| CL2018000730A1 (es) | Compuestos heterocíclicos y usos de los mismos | |
| CL2020001546A1 (es) | Compuestos de 4-azaindol. | |
| CL2018003323A1 (es) | Piridinas sustituidas con heteroarilo y métodos de uso. | |
| CO2017013229A2 (es) | Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| SV2017005514A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| NI201800075A (es) | Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos. | |
| CL2018000953A1 (es) | 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj) | |
| CO2017006214A2 (es) | Derivados de quinazolina utilizados para tratar el vih | |
| CO2019009373A2 (es) | Compuestos heterocíclicos útiles como inhibidores duales de atx/ca. | |
| CU20160162A7 (es) | Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen | |
| MX2016012984A (es) | Derivados indol para uso en medicina. | |
| SV2017005405A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| CR20160321A (es) | Modulares de tetrahidropiridopirazinas de gpr6 | |
| CU24410B1 (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| CR20170118A (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
| CL2019001458A1 (es) | Nuevos derivados de isoxazolil éter como pam de gaba a alfa5. | |
| AR075975A1 (es) | Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3 | |
| MX384847B (es) | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat). | |
| CL2018003121A1 (es) | Inhibidores del potenciador del homólogo zeste 2. | |
| MX2017011650A (es) | Inhibidores de kv1.3 y su aplicacion medica. |